The Biosimilars Market in 2026

The global biosimilars market was worth about $40.4 billion in 2025 and is forecast to reach $191.29 billion by 2035, a compound annual growth rate of roughly 16.8% (Precedence Research, 2025). Grand View Research puts the 2025 figure slightly lower at $39.6 billion and models an 18.4% CAGR through 2033 (Grand View Research, 2025), so a plan that models a mid-teens to high-teens growth rate sits inside the credible range whichever source a reader prefers.

What drives that curve is a wave of expiring biologic patents. Blockbusters such as adalimumab (Humira), ustekinumab (Stelara), aflibercept (Eylea) and denosumab (Prolia) have lost or are losing exclusivity, and each opens a multi-billion-dollar reference segment to competition. By late 2025 the FDA had approved roughly 78 biosimilars, of which 21 carried an interchangeable designation (GaBI Online, 2025); 18 of those approvals landed in 2025 alone, spanning six therapeutic areas as the field diversifies past oncology and inflammation.

The savings story is what keeps payers and governments behind the category. US biosimilars have delivered more than $56 billion in cumulative savings (Cardinal Health, 2025), and adalimumab biosimilars alone averaged around $4,505 in annual savings per patient after the 2023 US launches. In the UK, the NHS has used biosimilar switching programmes in rheumatology and gastroenterology to redirect hundreds of millions of pounds of drug spend, which is exactly why the commissioning environment favours new entrants that can supply reliably and price sensibly.

Two structural facts should sit at the front of any biosimilars business plan. First, this is not a generics market: a biosimilar cannot be an identical copy of a biologic grown in living cells, so it competes on trust, supply reliability and modest price advantage rather than a race to the bottom. Second, the category is concentrating. Sandoz leads with more than 18% share, and the top five players — Sandoz, Pfizer, Amgen, Celltrion and Biocon — hold roughly 55% of the market between them (Alira Health, 2025). A credible new entrant either brings a manufacturing cost advantage, a specific geographic or therapeutic focus, or a commercial route the incumbents undervalue. The plan has to name which of those it is on page one.

Who you are up against

The competitive section of a biosimilar plan should be specific about the incumbents, because investors know them by name. Sandoz built its lead by growing biosimilar revenue at roughly 18% a year and, in 2024, acquired the Cimerli ophthalmology business to strengthen its US position ahead of an aflibercept launch. Amgen turned its heritage as a biologics innovator into a portfolio that has generated more than $13 billion in biosimilar sales since 2018. Samsung Bioepis had launched 11 US biosimilars by early 2026 and is targeting 20 by 2030. Celltrion, Biocon Biologics, Pfizer, Viatris, Fresenius Kabi, Coherus and Teva round out a field where scale, manufacturing cost position and breadth of portfolio are the durable advantages.

What that means for a plan is straightforward: do not claim you will out-scale these companies. Win instead on a defined slice — a specific molecule where competitive density is still low, a single reimbursement system you can serve better than a global player bothers to, or a cost position from a regional CDMO that lets you hold margin at a sharper discount. The competitive analysis should map each incumbent's likely response and show why your beachhead is defensible before they react.

Questions Founders Ask First

These are the queries that show up before anyone downloads a template. Answering them cleanly inside the plan removes the objections an investor or lender raises in the first meeting.

Is a biosimilar the same as a generic?

No, and the difference is commercial, not just chemical. A generic is a molecule-for-molecule copy of a small-molecule drug and, once several generics compete, prices can fall more than 95%. A biosimilar is a highly similar version of a large biologic that can never be identical, so regulators require it to show no clinically meaningful differences in safety, purity and potency. In practice biosimilars discount the reference product by 15–35% and take around half of prior brand volume over time, which means the business is built on durable moderate margins rather than a fast collapse in price.

How long is the reference biologic protected?

In the US, the BPCIA grants a reference biologic 12 years of exclusivity from first licensure before a biosimilar can be approved, layered on top of any patents still in force. The BPCIA "patent dance" — the structured exchange of patent lists and litigation between originator and biosimilar developer — often decides the real launch date. Your pipeline schedule is driven by each molecule's exclusivity clock, not by how fast the science is ready.

Does interchangeability actually move sales?

Less than founders expect. Real-world US data shows that interchangeable status has had limited impact on uptake compared with where a product sits on the formulary. Only about 3% of adalimumab patients used the interchangeable option that avoids a new prescription, and switching has been driven far more by pharmacy benefit manager decisions than by the interchangeable label. Model interchangeability as a helpful lever, not the growth engine.

Can a small company realistically enter?

Yes, but usually not by developing a molecule from scratch. Smaller entrants typically in-license an approved biosimilar for a specific market, partner with a contract manufacturer, or build a services business around the category. The three-model comparison below is the honest map of what "entering biosimilars" can mean at different capital levels.

Three Ways to Build a Biosimilar Business

"Biosimilars" is not one business model. The single most useful thing a plan can do early is state which of these three the venture is, because the capital, timeline, risk and investor type differ completely. Most failed biosimilar plans quietly mix the economics of one model with the capital plan of another.

The full-developer model is where the headline $100M–$300M number comes from, and where the interesting margins ultimately live if you can carry a portfolio. The commercialization-partner model is how most first-time founders realistically enter: you license rights to an already-approved biosimilar such as an adalimumab or trastuzumab product and build the sales, distribution and market-access engine in one country or region. The services model — a GMP analytical characterization lab, a biosimilar-focused regulatory consultancy, or a specialty distributor — is the only one where a conventional small-business loan is even relevant, because its capital needs sit in the hundreds of thousands rather than the hundreds of millions.

If you are weighing an adjacent path, our biopharmaceutical business plan template covers the wider novel-biologics case, while this page stays focused on the specific economics of copying an off-patent biologic.

Choosing Your First Molecule

The choice of target biologic is the single most consequential decision in a biosimilar plan, because it fixes the size of the prize, the strength of the competition, the length of the exclusivity clock, and the difficulty of the science. A strong plan does not just name a molecule — it justifies the choice against those four filters and shows why this venture is well-placed to win that specific fight.

The current wave of opportunity comes from biologics that have recently lost, or are about to lose, exclusivity. The reference segments below give a sense of scale, and each has a distinct competitive picture that your plan should map before committing:

• Adalimumab (Humira): the category's proving ground, with nine or more US biosimilars already competing. High awareness, but crowded and price-competitive — a plan here must lead with a manufacturing cost advantage or a specific channel edge.
• Ustekinumab (Stelara): a large immunology segment that opened to biosimilar competition in 2025, with interchangeable approvals already landing. Still early enough for a well-timed entrant to take meaningful share.
• Aflibercept (Eylea): a high-value ophthalmology reference product where the first biosimilars arrived from 2024. Specialist prescribing and buy-and-bill dynamics reward a focused commercial motion.
• Denosumab (Prolia / Xgeva): a bone-health segment with recent biosimilar entries and strong volume potential across osteoporosis and oncology support.
• Tocilizumab and trastuzumab: established biosimilar categories in inflammation and oncology where a portfolio play, rather than a solo launch, is the realistic route to durable share.

Two filters separate a fundable molecule choice from a naive one. The first is competitive density: entering a segment that already has half a dozen approved biosimilars means competing on price and supply reliability against Sandoz, Amgen or Celltrion, so the plan needs a genuine cost or channel edge. The second is the extrapolation opportunity — how many indications a biosimilar can inherit from the reference product without separately studying each one, which directly sets the addressable market. A molecule with broad extrapolation potential and moderate competitive density is worth more to a founder than a bigger segment that is already saturated.

For a portfolio venture, the sequencing question matters as much as the selection. Staggering launches against successive patent cliffs smooths revenue and lets the commercial and regulatory teams reuse hard-won capability across molecules. The financial model should show that sequencing explicitly, because a lumpy single-launch forecast reads as fragile to the strategic partners and life-sciences funds that back this category.

Startup Capital & How Ventures Get Funded

A full biosimilar development program costs $100 million to $300 million and takes six to nine years from analytical characterization to approval, with comparative clinical work absorbing roughly 57% of the budget (McKinsey, 2025). That is the number to plan against for an own-molecule venture. Below it, the commercialization-partner and services models cost a fraction — but they still need a costed, staged budget, because investors fund milestones, not ambitions.

Where the money goes on a full program

• Cell-line development & analytical characterization: $8M–$25M (£6M–£20M) — proving structural and functional comparability to the reference product
• Comparative clinical program (PK/PD, plus any efficacy): $40M–$170M (£32M–£135M) — the single largest and most schedule-sensitive line
• GMP manufacturing scale-up / CDMO: $20M–$80M (£16M–£64M) — process development, tech transfer and validation batches
• Reference-product drug purchase for trials: $5M–$25M (£4M–£20M) — you must buy the branded biologic at list price to compare against it
• Regulatory filing (BsUFA III BLA fee, QA, submission): $3M–$12M (£2.4M–£9.5M) — including the FDA program user fees under BsUFA III

How biosimilar ventures actually get funded

Ordinary startup finance does not stretch to a nine-figure clinical program, so the funding mix is different from most business plans. The realistic routes are:

• Strategic partnership / co-development: a larger pharma or generics company funds development in exchange for rights or a profit share — the most common way expensive molecules get to the line
• Venture and growth equity: specialist life-sciences funds back either a molecule portfolio or a commercialization platform; a Series A of $10M–$40M is typical for the commercialization-partner model
• Non-dilutive grants: in the US, BARDA and NIH support specific programmes; in the UK, Innovate UK and the Biomedical Catalyst fund early biomanufacturing and process innovation
• Debt and small-business loans: only realistic for the services model — a US SBA 7(a) loan (up to $5M) or a UK Start Up Loan (up to £25,000) can capitalize a lab, consultancy or distributor, not a molecule

This is the section where a generic template fails a biosimilar founder. Our Research + Content package builds a staged funding plan and a five-year model that ties each capital tranche to a development or commercial milestone, which is what a strategic partner or a Series A lead expects to interrogate before they commit.

Manufacturing & Operations

Manufacturing is where biosimilars are won or lost, because the whole commercial thesis rests on delivering a comparable biologic at a lower cost than the originator while supplying it reliably at scale. Unlike a small-molecule generic, a biosimilar is produced in living cells, so process consistency is not a detail — it is the product. Any plan that treats manufacturing as an afterthought will not survive investor diligence.

The make-versus-buy decision

Few new entrants build their own biologics plant; a large-scale GMP facility runs to hundreds of millions and years of construction. The realistic choice is a contract development and manufacturing organization (CDMO). Naming a credible CDMO strategy — whether a global player such as Samsung Biologics or a regional partner near your target market — signals to investors that supply is de-risked. The plan should state expected cost of goods as a percentage of net sales, the number of validated batches planned, and the redundancy strategy for a single point of failure, because a supply interruption in a switched patient population is both a clinical and a reputational risk.

Cell line, characterization and comparability

For an own-molecule developer, the operational spine is the cell line and the analytical package that proves comparability. This is the work that establishes structural and functional similarity to the reference product across dozens of quality attributes, and it is what a regulator scrutinizes first under the streamlined pathways now emerging. The plan should describe the analytical platform, the immunogenicity assessment approach, and how process changes will be controlled over the product's life so that a batch made in year five is comparable to the one that was approved.

Quality systems and supply reliability

A biosimilar business lives under continuous GMP obligations: batch release, pharmacovigilance, cold-chain logistics for many biologics, and the quality management system that ties them together. For a commercialization-partner model, much of this sits with the licensor, but the venture still owns market-facing pharmacovigilance and distribution. Spelling out who holds each responsibility — and the service-level commitments behind supply — turns an operations section from boilerplate into evidence that the team understands the category.

Where Biosimilar Businesses Cluster

Location matters more in biosimilars than in most industries because talent, manufacturing capacity and regulatory proximity are concentrated. A plan that names its base and its manufacturing route — rather than gesturing at "global operations" — reads as credible.

• Boston / Cambridge, Massachusetts: the densest US biologics talent pool and the natural base for a US-facing developer or commercialization platform
• Research Triangle, North Carolina: large-scale biomanufacturing capacity and CDMO presence, lower cost than the coasts
• San Francisco Bay Area: deep venture capital and biologics science, strongest for platform and analytics plays
• Cambridge & Stevenage, UK: the UK's core life-sciences corridor, with the Cell and Gene Therapy Catapult and strong access to MHRA and Innovate UK
• Incheon, South Korea: home to Samsung Bioepis and Celltrion, and the largest concentration of contract biomanufacturing capacity worldwide
• Bangalore, India: Biocon Biologics' base and a low-cost route to GMP manufacturing and analytical work for globally-focused entrants

For a commercialization-partner model, the relevant "location" is the target market's reimbursement system: the US pharmacy benefit manager channel, England's NHS commissioning and switching frameworks, or Germany's quota-based biosimilar substitution rules. Each rewards a different commercial motion, and your plan should pick one to win first rather than spread thinly across all of them.

How Biosimilar Businesses Make Money

Biosimilar revenue is a function of three variables: the discount to the reference biologic, the volume share captured, and the size of the reference segment. Biosimilars typically launch at 15–35% below the reference list price and capture roughly 50% of prior brand volume over time as payers and formularies switch (Biosimilar Development, 2025). Unlike a generic, the price does not collapse, so the model is about durable share rather than a one-time volume spike.

Worked example — a commercialization partner

Suppose a venture in-licenses an approved adalimumab biosimilar for a single mid-size European market where the reference segment is worth $400 million a year. It launches at a 30% discount and, over three years, reaches a 25% volume share. At that share and discount, net product sales work out to roughly $70 million a year. After cost of goods (supplied by the licensor or a CDMO), a sales and market-access team, and a licensing royalty back to the developer, a disciplined operator can hold a mid-teens operating margin — enough to justify a $15M–$25M raise against an 18-month path to revenue.

Worked example — a services business

The economics look completely different for the services model, and that difference is why the plan must state which model it is. Consider a biosimilar-focused regulatory and analytical consultancy: it might launch on $400,000 of founder and angel capital, bill developers on a project and retainer basis, and reach profitability inside a year. A ten-person team charging out at day rates typical for specialist life-sciences consulting can support several million dollars of annual revenue at a healthy services margin, with the reference-product and clinical costs sitting on the client's balance sheet rather than its own. It never touches the $100M–$300M development figure — a reminder that "entering biosimilars" spans two orders of magnitude of capital depending on the model.

Where additional revenue comes from

• Portfolio breadth: carrying several molecules spreads clinical and commercial failure risk and smooths revenue across patent cliffs
• Multi-market rights: the same in-licensed biosimilar sold across several reimbursement systems multiplies the base with limited extra development cost
• Patient-support and adherence services: higher persistence lifts the durable share that underpins the whole model
• Manufacturing or analytical services: selling spare GMP or characterization capacity to other developers turns a cost centre into a revenue line

The proof that scale pays: Amgen has booked more than $13 billion in biosimilar sales since 2018, and Sandoz built the leading position by growing biosimilar revenue at roughly 18% a year. Neither did it on a single molecule. Your financial model should show the portfolio and multi-market logic explicitly, because a single-product biosimilar plan looks fragile to anyone who understands the category.

Approval Pathways: FDA, MHRA & EMA

Regulatory strategy is a business decision, not a back-office one, because the trial design a regulator will accept sets most of your development budget. The encouraging news for new entrants is that the three major agencies are moving, in parallel, toward accepting less clinical data — which lowers the cost of entry.

United States (FDA)

• Approval via the 351(k) abbreviated Biologics License Application under the Biologics Price Competition and Innovation Act (BPCIA, 2009)
• Reference product carries 12 years of exclusivity before a biosimilar can be licensed
• Program user fees set under BsUFA III (fiscal years 2023–2027), which also defines review timelines and meeting types
• Optional interchangeability designation allows pharmacy-level substitution; in 2025 the FDA proposed streamlining the switching-study requirement
• In 2025 the FDA also proposed dropping routine comparative efficacy studies where analytical and PK comparability is strong

United Kingdom (MHRA)

• Licensed by the MHRA, which since 2021 has accepted that a comparative efficacy trial is often unnecessary where the applicant has a sound scientific rationale
• Heavier reliance on comparative analytical and functional data plus known clinical experience of the originator
• Commercial uptake shaped by NHS regional switching programmes and commissioning, which actively favour biosimilar adoption

European Union (EMA) and beyond

• In June 2025 the EMA published a draft reflection paper proposing a streamlined pathway that waives confirmatory comparative efficacy studies where six or more independent batches demonstrate comparability; consultation ran to 30 September 2025
• Germany operates quota-based biosimilar substitution, one of the most entrant-friendly reimbursement systems
• Manufacturing hubs in South Korea and India supply much of the global GMP capacity, so a plan should name its CDMO strategy and where its batches will be made

A biosimilar plan should model at least two regulatory scenarios: the current standard, and the streamlined pathway that FDA, MHRA and EMA are converging on. If the streamlined route becomes standard for your target molecule, it can cut tens of millions from the clinical line — a swing large enough that investors will want to see it built into the model rather than mentioned in passing.

Biosimilar Terms Your Plan Must Get Right

Biosimilars are jargon-heavy, and misusing a term is an instant credibility loss with an investor or a regulator. Define these plainly, and tie each to the plan section it affects.

• Reference product: the originator biologic your product is compared against and priced below; its exclusivity clock drives your launch date
• Comparability: the evidence package showing no clinically meaningful differences in safety, purity and potency — the core of the regulatory case
• 351(k) pathway: the US abbreviated BLA route that lets you rely on the reference product's established safety and efficacy
• Interchangeability: a US designation permitting pharmacy substitution without prescriber involvement, subject to state law
• Immunogenicity: the risk that patients mount an immune response to the biologic; a key safety endpoint that clinical work must address
• Extrapolation: approval for indications not directly studied, based on comparability — a major driver of a biosimilar's addressable market
• BsUFA: the Biosimilar User Fee Act that funds and times FDA review; BsUFA III covers 2023–2027
• Patent dance: the structured BPCIA exchange of patents and litigation that frequently sets the true commercial launch date

Mistakes That Sink Biosimilar Plans

Across biologics and healthcare plans we review, the same avoidable errors show up. Each one is easy to fix before an investor sees it.

• Modelling it like a generic. Assuming a 90%+ price collapse and near-total volume capture. The reality is a 15–35% discount and roughly half the volume — get this wrong and the whole forecast is fiction.
• Underbudgeting the reference-product purchase. You must buy the branded biologic at list price to run comparative trials, which can run to tens of millions and is routinely forgotten.
• Treating interchangeability as the growth engine. Formulary placement and payer contracting move volume; the interchangeable label helps at the margin.
• Ignoring the exclusivity clock. Sequencing a pipeline without mapping each molecule's 12-year US exclusivity and patent cliff leads to launches that are legally impossible on the stated date.
• Betting the company on one molecule. A single clinical or legal setback ends a single-product venture; a portfolio spreads the risk and is what sophisticated investors expect.

Sample Business Plan Preview

Here is an extract from a biosimilars business plan written by our team, so you can see the level of specificity investors in this category expect:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured and, for biosimilars, prompted with the specific detail this category demands:

• Executive Summary — Target molecule, chosen business model, and the funding ask in 60 seconds
• Company Overview — Legal structure, founding team's regulatory and commercial credibility, and base location
• Market Analysis — Reference segment size, patent cliffs, competitor share, and the 15–35% discount thesis
• Regulatory Strategy — 351(k) / MHRA / EMA pathway choice, exclusivity clock, and the streamlined-trial scenario
• Operations & Manufacturing — CDMO strategy, analytical characterization, and supply reliability
• Commercial Plan — Market-access motion by reimbursement system, formulary strategy, and field model
• Management Team — Founder bios, scientific advisory board, and key regulatory and commercial hires
• Financial Forecast — Milestone-linked capital plan and a five-year model with discount, share and margin sensitivities

The Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides the five-year Excel model — income statement, cash flow, balance sheet, break-even and funding-tranche schedule — that a strategic partner or Series A lead will stress-test line by line.

Frequently Asked Questions